<?xml version="1.0" encoding="UTF-8"?>
<p>GSK1838705A (
 <xref ref-type="fig" rid="molecules-26-00438-f005">Figure 5</xref>, Compound 
 <bold>34</bold>) inhibits ALK, with an IC
 <sub>50</sub> of 0.5 nmol/L resulting in the complete regression of ALK-dependent tumors in vivo at well-tolerated doses. Based on this, GSK1838705A is a promising antitumor agent for therapeutic use in human cancers [
 <xref rid="B75-molecules-26-00438" ref-type="bibr">75</xref>,
 <xref rid="B76-molecules-26-00438" ref-type="bibr">76</xref>].
</p>
